Filippov Av
A5022598841- Tuberculosis Research and Epidemiology
- Infectious Diseases and Tuberculosis
- Diagnosis and treatment of tuberculosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Pneumonia and Respiratory Infections
- Colorectal Cancer Surgical Treatments
- Neurological Disorders and Treatments
- Colorectal and Anal Carcinomas
- Pharmacovigilance and Adverse Drug Reactions
- Drug-Induced Adverse Reactions
- Peripheral Artery Disease Management
- Immunodeficiency and Autoimmune Disorders
- Diphtheria, Corynebacterium, and Tetanus
- Liver Disease Diagnosis and Treatment
- Immune responses and vaccinations
- Pharmaceutical studies and practices
- Pain Management and Treatment
- Biosimilars and Bioanalytical Methods
- Human Health and Disease
- Gastrointestinal Bleeding Diagnosis and Treatment
- Streptococcal Infections and Treatments
- Esophageal and GI Pathology
- Helicobacter pylori-related gastroenterology studies
- Liver Disease and Transplantation
- Gastrointestinal disorders and treatments
Government of Russia
2017-2021
Westmead Hospital
2021
The University of Sydney
2021
Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) are lacking. This study aimed evaluate the safety effectiveness of bedaquiline-containing regimens in a large, retrospective, observational conducted 25 centres 15 countries five continents.428 culture-confirmed MDR-TB cases were analysed (61.5% male; 22.1% HIV-positive, 45.6% XDR-TB). admitted hospital for median (interquartile range (IQR)) 179 (92-280) days exposed 168...
The World Health Organization (WHO) recommends that countries implement pharmacovigilance and collect information on active drug safety monitoring (aDSM) management of adverse events.The aim this prospective study was to evaluate the frequency severity events anti-tuberculosis (TB) drugs in a cohort consecutive TB patients treated with new (i.e. bedaquiline, delamanid) repurposed clofazimine, linezolid) drugs, based WHO aDSM project. Adverse were collected prospectively after attribution...
The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. aim study is to prospectively evaluate effectiveness bedaquiline (and/or delamanid)- containing regimens a large cohort consecutive TB patients treated globally. This observational, prospective based on data collected and provided by Global Tuberculosis Network (GTN) centres analysed twice year. All (including children/adolescents) with and/or delamanid...
The objective of the study: to determine efficacy and safety chemotherapy regimens with bedaquiline in patients respiratory tuberculosis context everyday clinical practice minimal non-inclusion criteria. Subjects methods. In a prospective, open-label, non-randomized, single-center trial which included 315 patients, were evaluated, when prescribing regimen priority was given bedaquiline, linezolid, levofloxacin/moxifloxacin, cycloserine/terizidone. Patients followed up for at least 24 months,...
The objective : safety assessment of chemotherapy regimens compiled in accordance with the recommendations World Health Organization (WHO), 2019, patients multiple drug resistant tuberculosis (MDR) clinical practice settings. Subjects Frequency, patterns, severity and risk factors adverse events (AE) WHO as 2019 were analyzed 122 MDR XDR respiratory within programmatic use new anti-tuberculosis drugs. Results . frequency AE made 64.8% (95% CI 55.9-72.7%), gastrointestinal, cardiovascular...
The objective: to justify the optimal duration of chemotherapy with Lzd and Bdq by evaluating long-term treatment outcomes in patients multiple/pre-extensive drug resistant (MDR/preXDR) tuberculosis who interrupted at different time points. Subjects Methods. 800 MDR/preXDR were enrolled study, they from all regions Russian Federation started a course regimens containing 2017-2018. All their (124) divided 4 groups. Group 1-43 received less than 90 doses, 2-37 91 180 3-39 181 270 4-5 271 360...
Summary .88 HIV-infected patients with tuberculosis of different sites were tested using a skin test recombinant allergen Mycobacterium (Diaskintest®). The was positive in 35 cases. In the involved study, 95 % confidence interval (CI) for sensitivity 30 to 40 %. We found correlation between peripheral blood CD4+ lymphocyte number and rate Diaskintest®. > 400 lymphocytes per 1 mL–1 had reactions reliably more often than those < 200 mL–1. also established extension Diaskintest®: proportion...